Evident Vascular Receives Financing for IVUS Platform Development

October 17, 2023—Evident Vascular, Inc., medical technology startup, announced that it has launched with a $35 million Series A financing from Vensana Capital.

Evident Vascular is developing a next-generation intravascular ultrasound (IVUS) platform leveraging artificial intelligence to enable superior imaging and streamlined workflow.

According to the company, its IVUS platform technology is designed initially for peripheral vascular interventions, with future capability for coronary procedures. Evident Vascular technology is intended to expand adoption of IVUS by enabling improved clinical outcomes with faster and more accurate diagnosis and treatment decisions.

Howard Rosen is CEO and Cofounder of Evident Vascular.

“Legacy IVUS platforms were originally designed primarily for coronary procedures and secondarily for peripheral vascular applications,” commented Rosen in the company’s press release. “Shortcomings in image quality, interpretation, and workflow have limited the widespread adoption of IVUS despite its clinical benefit, and there has been minimal innovation to address these limitations.”

Rosen added, “Along with my cofounders, Chief Technology Officer Patrick Phillips, PhD, and Chief Product Officer Danielo Piazza, our team is pioneering the future of intravascular imaging with a platform optimized for peripheral vascular procedures that will enable improved image interpretation guidance, and ease of use enhancements throughout the clinical workflow.”

Vensana Capital is a venture capital and growth equity investment firm launched in 2019 that is investing in development and commercial-stage companies across the Medtech sector. Vensana manages $550 million in capital, noted the press release from Evident Vascular.